Exabis Library
Welcome to the e-CCO Library!
DOP070: The relationship between vedolizumab drug concentrations at or before week 6 and remission at week 14 in ulcerative colitis patients from GEMINI 1
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP071: Comparison of endoscopic responses to adalimumab monotherapy and combination therapy with azathioprine in patients with Crohn's disease: a sub-analysis of DIAMOND trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP071: Tight control with adalimumab-based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP071: Tofacitinib plasma concentration monitoring is not needed for optimisation of induction therapy in moderate-to-severe ulcerative colitis: results of pooled exposure-response analyses of Phase 3 induction studies
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP072: Achieving biochemical remission with adalimumab therapy using therapeutic drug monitoring: Results of a large prospective Crohn’s disease cohort
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP072: Assessment of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) using central video review of colonoscopies in paediatric patients with ulcerative colitis: data from the Canadian Children IBD Network
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP072: Association of ustekinumab trough concentrations with clinical, biochemical, and endoscopic outcomes
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP073: Incidental diagnosis of inflammatory bowel disease through bowel cancer screening: a 7-year experienceU. Nosegbe*1, J. A. Scott1, R. O. Butcher1, 2, A. M. Abbasi1, R. C. Prudham1, R. George1, J. Limdi1, 2
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP073: Results of the sixth ECCO Scientific Workshop: The pathogenesis of inflammatory extraintestinal manifestations of inflammatory bowel disease: implications for research, diagnosis, and therapy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP073: Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided ulcerative colitis patients with moderate-to-severe disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP074: IL-33 promotes gut mucosal wound healing by inducing miRNA-320 to stimulate epithelial restitution and repair
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP074: Incidence and prediction of fistula formation in England
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP074: Pharmacokinetics and exposure-response of tofacitinib in a Phase 3 maintenance study in ulcerative colitis patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP075: Colonic gamma delta t-cells respond innately to NKG2D ligands and are grossly dysregulated in active inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP075: Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP075: Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP076: A Danish cross-sectional study: autoimmune and chronic inflammatory disorders associated with ulcerative colitis.
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP076: A phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinab, an oral JAK inhibitor, in patients with moderately to severely active ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP076: IL-3 drives IL-10-secreting Tr1 cells to counteract experimental colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP077: Deep immunophenotyping reveals a role for Mucosal Associated Invariant T (MAIT) cells in the response to anti-TNF treatment in Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM